Vaginitis Treatment Market is set to reach USD 2.7 Bn in 2020, and witness a CAGR of around 5% during 2020 to 2030
Future Market Insight’s latest report on the vaginitis treatment drugs market establishes that growth is anticipated to be positive, registering a CAGR of 5% between 2020 and 2030. The global vaginitis treatment drugs market is expected to witness stupendous growth during the tenure of 2020–2030. This growth is attributed to increased cases of bacterial vaginosis and complicated vulvovaginal candidiasis (VVC) in worldwide locations. Lincosamide antibiotics, nitroimidazole compound, imidazoles, and triazoles are some of the important medicines used for the treatment of vaginosis.
It has been discovered that vaginal infections plague two-fifths of the women population across the world. Vaginitis can lead to serious complications and risks such as miscarriage, pre-mature births and HIV-AIDS if left untreated. Other diseases such as gonorrhea, chlamydia and papillomavirus are also known to occur as potential complications. A key problem in detecting vaginitis is that a majority of the patients are asymptomatic. This leads to difficulties in prescribing appropriate medications.
The abovementioned trends have therefore made it a top priority for healthcare players to accelerate research in the detection, diagnosis and treatment of vaginitis infections. One of these approaches is developing appropriate drug formulations, which have witnessed a major upsurge in the past few years. Constant innovations in treatment are being discovered, placing the market on a higher pedestal in the forecast period.
“The vaginitis treatment drugs market is slated to remain positive, with manufacturers concentrating on introducing non-antibiotic drugs as a long-term treatment solution in the wake of a high infection recurrence rate. Players are introducing single-dose and over-the-counter drugs which provide cost effective treatment,” infers an FMI analyst.
Request a Sample Report with Table of Contents and Figures: https://www.futuremarketinsights.com/reports/sample/rep-gb-11790
Key Takeaways from FMI’s Vaginitis Treatment Drugs Report
- Vaginitis treatment drugs market is slated to reach a valuation of ~US$ 3 Bn by the end of 2020
- Nitro Imidazole compounds are the largest revenue generators by drug type, registering a revenue share of 44% across the forecast period
- By schedule, prescription drugs dominate the vaginitis treatment drugs market, contributing 75% of the market value
- Growing recurrence of bacterial vaginosis and complicated vulvovaginal candidiasis (VVC) remains a principal growth accelerator
Vaginitis Treatment Drugs Market- Key Trends
- Online pharmacies account for maximum transactions of vaginitis treatment drugs. The outbreak of the coronavirus pandemic has accelerated usage of online retail outlets in order to minimize the risk of exposure to the virus when visiting an actual pharmacy
- At least half of the women with bacterial vaginosis are asymptomatic. As a result, treatment gets delayed and complications keep compounding. This has spurred market players to accelerate innovations making it possible to detect asymptomatic cases
Vaginitis Treatment Drugs Market- Region-wise Analysis
- Europe’s vaginitis treatment drugs market accounts for a quarter of the global vaginitis treatment drugs market. Increased supply of vaginal tablets in pharmacies is stimulating market growth
- North America remains the most lucrative market, with the United States capturing the leading share. A higher rate of over the counter medicine availability is providing impetus for further growth
- South Africa and Brazil also represent credible opportunities as both are developing nations with a high incidence of vaginal infections
Vaginitis Treatment Drugs Market- Competitive Landscape
The vaginitis treatment drugs market is experiencing an influx of novel drugs. A number of clinical trials, drug development projects, establishment of distribution channels and e-commerce platforms are being witnessed. The market is highly consolidated, with over 25 players capturing a major chunk of the market.
The market players are incorporating nitro imidazole, tinidazole and metronidazole compounds in their formulations to manufacture vaginitis drugs. They are also concentration on strategic collaborations to introduce new drugs, such as the one between Basilea Pharmaceutica Ltd and Pfizer Inc in December 2017. The two giants collaborated to develop and commercialize Cresemba, an isavuconazole-based drug in the Asia-Pacific region.
Recently, Plush Care collaborated with Lupin Pharmaceuticals to facilitate bacterial vaginosis treatment through the former’s virtual care platform. This enables patients to virtually seek appointments with doctors, discuss the symptoms and get prescribed for lab testing.
Our advisory services are aimed at helping you with specific, customized insights that are relevant to your specific challenges. Let us know about your challenges and our trusted advisors will connect with you: https://www.futuremarketinsights.com/customization-available/rep-gb-11790
Vaginitis Treatment Drugs Market Taxonomy
- Nitro Imidazole Compounds
- Lincosamide Antibiotics
- Bacterial Vaginitis
- Fungal Vaginitis (Yeast Infection)
Route of Administration
Schedule of Drug
- Prescription Drugs (Rx)
- Over-the-Counter Drugs (OTC)
- Hospital Pharmacies
- Retail Pharmacies
- Drug Stores
- Mail Order Pharmacies
- Nordic countries
- South Korea
- New Zealand
- Southern Africa
- Northern Africa
COVID -19: Impact Analysis@ https://www.futuremarketinsights.com/covid19/rep-gb-11790
More Insights on the Vaginitis Treatment Drugs Market
Future Market Insights brings the comprehensive research report on forecasted revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2015 to 2030. The global Vaginitis Treatment Drugs Market is segmented in detail to cover every aspect of the market and present a complete market intelligence approach to the reader. The study provide compelling insights on Vaginitis Treatment Drugs Market on basis of drug type (nitroimidazole compound, lincosamide antibiotics, triazoles, imidazoles), indication (bacterial vaginitis, fungal vaginitis (yeast infection), trichomoniasis), route of administration (oral, cutaneous, vaginal), schedule of drug (prescription drugs (Rx), over-the-counter drugs (OTC)) distribution channels (hospital pharmacies, retail pharmacies, drug stores, mail order pharmacies) across seven major regions.
Explore Extensive Coverage on FMI’s Healthcare, Pharmaceuticals and Medical Devices Market
Candida Vaginitis Rapid Testing Market: FMI’s ongoing research project on the candida vaginitis rapid testing market offers comprehensive analysis of the business models, key strategies and respective market shares of some of the most prominent players in the competition landscape. It also offers insights regarding prominent dynamics influencing the growth of the market.
Women’s Health Diagnostic Testing Market: The women’s health diagnostic testing market study-in-progress establishes that the market is set to broaden in scope throughout the forecast period until 2027. The market is segmented based on application type and end-user across prominent regions.
Cervical Implants Market: The cervical implants market report offers a comprehensive analysis of prominent drivers, opportunities and restraints associated with the growth of the market across various segments in seven prominent regions.
About Future Market Insights (FMI)
Future Market Insights (FMI) is a leading provider of market intelligence and consulting services, serving clients in over 150 countries. FMI is headquartered in London, the global financial capital, and has delivery centers in the U.S. and India. FMI’s latest market research reports and industry analysis help businesses navigate challenges and take critical decisions with confidence and clarity amidst breakneck competition. Our customized and syndicated market research reports deliver actionable insights that drive sustainable growth. A team of expert-led analysts at FMI continuously track emerging trends and events in a broad range of industries to ensure that our clients prepare for the evolving needs of their consumers.
Mr. Abhishek Budholiya
Unit No: AU-01-H Gold Tower (AU), Plot No: JLT-PH1-I3A,
Jumeirah Lakes Towers, Dubai,
United Arab Emirates
MARKET ACCESS DMCC Initiative
For Sales Enquiries: firstname.lastname@example.org
For Media Enquiries: email@example.com
Press Release Source: https://www.futuremarketinsights.com/press-release/vaginitis-treatment-drugs-market